Insights & Publications


The Value of Remote Monitoring in Point-of-Care Testing

From ensuring proper instrument function to quality control, laboratories are using point-of-care testing technology to boost efficiency and patient safety. Author: Alice Pedersen, MBA, MLS(ASCP) // Date: MAR.1.2024 // Source: Clinical Laboratory News   When asked why point-of-care (POC) testing is gaining popularity, the most common answer is real-time test results; next is cost efficiency…

Read More

In ED/urgent cares, the lab tests and the POC team

December 2023—A point-of-care testing team from TriCore was part of standing up three dual emergency department/urgent care centers in as many years, with a fourth set to open in March 2024. “They are super busy, as was expected. There’s a great need for this type of site,” says Kathleen David, MT(ASCP), TriCore’s associate director for…

Read More

Understanding Clinician Perspective for a Successful Point-of-Care Urine Drug Screen Test Implementation

Understanding clinician perspective for a successful point-of-care urine drug screen test implementation Nov. 20, 2023 Alice Pedersen, MBA,BS MLS(ASCP) Photo 176460444 © Olga Ostapenko | Though it is known that point-of-care (POC) urine drug screening (UDS) has its limitations, clinicians request POC UDS due to its convenience and cost effectiveness. Common clinical recommendations are…

Read More

Applying Laboratory Quality Principles to Real World Point-of-Care Testing Systems

Kathleen David, MT (ASCP) Jeanne Mumford, MLS (ASCP)     For a printable version of the August CE Story and test go HERE or to take test online go HERE. For more information, visit the Continuing Education tab. LEARNING OBJECTIVES Upon completion of this article, the reader will be able to: 1. Discuss the need for a quality…

Read More

Utility of Commercially Available Quantitative hCG Immunoassays as Tumor Markers in Trophoblastic and Non-Trophoblastic Disease

Abstract Background: The use of quantitative human chorionic gonadotropin (hCG) as a tumor marker is widely accepted despite lack of FDA-approval for oncology. Differences in iso- and glycoform recognition among hCG immunoassays is well established, exhibiting wide inter-method variability. Here, we assess the utility of 5 quantitative hCG immunoassays for use as tumor markers in…

Read More